ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
February 24, 2023 07:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
February 24, 2023 01:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
November 22, 2022 07:00 ET
|
ObsEva SA
Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 millionThe sale proceeds are expected to enable ObsEva to...
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
November 22, 2022 01:00 ET
|
ObsEva SA
Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 millionThe sale proceeds are expected to enable ObsEva to...
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
August 01, 2022 07:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – August 1, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel...
ObsEva Announces Corporate Updates
May 27, 2022 16:01 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Announces Corporate Updates
January 28, 2022 16:01 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – January 28, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
IPNav Closes on Debt Financing Facility
July 18, 2012 13:11 ET
|
IP Navigation Group, LLC
DALLAS, July 18, 2012 (GLOBE NEWSWIRE) -- IPNav announced today that the company has closed and drawn down on the first tranche of a $15 million debt financing facility with an affiliate of JGB...